HVB MINI FUTURE BULL - ASTRAZENECA | Real-time BOERSE MUENCHEN 07:16:15 14/06/2024 pm IST | ||
| 2.21 EUR | +7.80% |
|
| Current month | +9.04% | ||
| 1 month | +2.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 2.21 | +7.80% |
| 13/24/13 | 2.05 | -3.30% |
| 12/24/12 | 2.12 | +2.42% |
| 11/24/11 | 2.07 | -11.54% |
| 10/24/10 | 2.34 | +3.54% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 07:16 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD4MMP |
| ISIN | DE000HD4MMP7 |
| Date issued | 12/04/2024 |
| Strike | 10,667 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.36 € |
|---|---|
| Lowest since issue | 0.34 € |
| Spread | 0.01 € |
| Spread % | 0.45% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.1
USD
Average target price
174.4
USD
Spread / Average Target
+10.34%
- Stock Market
- Certificates
- Certificat
